Cell to Cure ApS is a Danish clinical-stage biotechnology company developing and manufacturing groundbreaking cell-based therapies for the treatment of severe diseases with unmet medical needs. The company focuses on off-the-shelf allogeneic mesenchymal stromal/stem cells (MSCs) derived from healthy donor adipose tissue, which can be used to modulate inflammation, promote tissue repair, and restore organ function.
Cell to Cure is a spin-out from the Cardiology Stem Cell Centre at Rigshospitalet, Copenhagen University Hospital, and has developed a proprietary manufacturing process for the production of clinical-grade cell products under GMP conditions, supported by its own in-house GMP manufacturing facility. The company’s products have demonstrated documented safety in more than 300 patients and are currently being evaluated in Phase I and II clinical trials with promising results.
The company develops its own clinical programs and collaborates globally with hospitals, research institutions, and commercial partners to expand the applications of its cell therapy platform. Key focus areas include diseases characterized by inflammation and immune dysregulation, such as autism and leaky gut syndrome, diabetic foot ulcers, non-ischemic heart failure, and eye diseases.
Cell to Cure is in the process of establishing its own clinical site in Fredericia Health Center to conduct Phase I and II clinical trials. The first trials at this facility will focus on the treatment of autism and leaky gut syndrome.
The Cell to Cure team possesses extensive expertise in cell biology, GMP manufacturing, regulatory affairs, clinical development, and business strategy, providing the company with a strong foundation for advancing innovative regenerative therapies from bench to bedside.
In addition, Cell to Cure is actively engaged in strategic partnerships and sublicensing to broaden the reach of its technology across multiple therapeutic areas. An example is the collaboration with Endeavour Cells ApS, which holds the rights to develop and commercialize Cell to Cure’s cell therapies for autism, ADHD, and related neurodevelopmental disorders.
With a solid scientific foundation, a scalable manufacturing platform, and a growing clinical pipeline, Cell to Cure ApS is positioned as a leading player in mesenchymal cell therapy and regenerative medicine.